siponimod has been researched along with Corneal-Neovascularization* in 1 studies
1 other study(ies) available for siponimod and Corneal-Neovascularization
| Article | Year |
|---|---|
Siponimod As a Novel Inhibitor of Retinal Angiogenesis: In Vitro and In Vivo Evidence of Therapeutic Efficacy.
Sphingosine-1-phosphate (S1P) receptors control endothelial cell proliferation, migration, and survival. Evidence of the ability of S1P receptor modulators to influence multiple endothelial cell functions suggests their potential use for antiangiogenic effect. The main purpose of our study was to investigate the potential of siponimod for the inhibition of ocular angiogenesis in vitro and in vivo. We investigated the effects of siponimod on the metabolic activity (thiazolyl blue tetrazolium bromide assay), cell toxicity (lactate dehydrogenase release), basal proliferation and growth factor-induced proliferation (bromodeoxyuridine assay), and migration (transwell migration assay) of human umbilical vein endothelial cells (HUVEC) and retinal microvascular endothelial cells (HRMEC). The effects of siponimod on HRMEC monolayer integrity, barrier function under basal conditions, and tumor necrosis factor alpha (TNF- Topics: Animals; Cells, Cultured; Corneal Neovascularization; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Rabbits; Retina; Tumor Necrosis Factor-alpha | 2023 |